ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 522

The Expression of mRNA for Peptidylarginine Deiminase Type 2 and Type 4 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis

Tatsuo Nagai1, Tetsuya Tomita2, Hideki Yoshikawa2 and Shunsei Hirohata1, 1Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 2Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Bone marrow, Gene Expression, polymerase chain reaction (PCR) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We previously showed
that bone marrow (BM) CD34+ cells from rheumatoid arthritis (RA) patients have
abnormal capacities to respond to tumor necrosis factor alpha and to
differentiate into fibroblast-like cells producing MMP-1, resembling type B synoviocyte. In addition, we have recently demonstrated
that the mRNA expression of nuclear factor kappa B1, Krüppel-like
factor 5 and FK506-binding protein 5 in BM CD34+ cells is significantly higher
in RA patients than osteoarthritis (OA) patients. Antibodies directed to citrullinated proteins are extremely specific for RA. Citrullination is catalyzed by a group of peptidylarginine deiminase (PAD) enzymes. PAD
family members are categorized into five isoforms (PAD1, 2, 3, 4 and 6).
Several studies have disclosed that PAD2 and PAD4 are expressed in rheumatoid
synovial tissue or in mononuclear cells of rheumatoid synovial fluid. Moreover,
Sp1 has been shown to regulate transcription of these PADI genes. The current
study therefore examined the mRNA expression of PADI2, PADI4 and Sp1
transcription factor in BM CD34+ cells from RA patients.

Methods: BM samples were obtained from 48 patients
with RA (6 males and 42 females: mean age 58.8 years) and 30 patients with OA
(3 males and 27 females: mean age 71.1 years), who gave informed consent, during joint operations via aspiration from iliac
crest. CD34+ cells were purified from the BM mononuclear cells by positive
selection with magnetic beads. The expression of mRNA for PADI2, PADI4 and Sp1
was examined by quantitative reverse transcription PCR and is shown as the
ratio of the copy numbers to those of
b-actin mRNA.

Results: The expression of mRNA for PADI2 was
significantly higher in RA BM CD34+ cells than OA BM CD34+ cells (Fig. A).
Compared to OA BM CD34+ cells, PADI4 and Sp1 gene expression levels of RA BM
CD34+ cells manifested no statistically significant increase (Fig. B and C). The
mRNA expression levels of PADI2, PADI4 and Sp1 were not correlated with serum
C-reactive protein or with the administration of methotrexate or oral steroid. PADI2 gene expression was significantly correlated with
PADI4 (p<0.0001, r=0.7143) and Sp1 (p<0.0001, r=0.7954) gene expression
in RA BM CD34+ cells.

Conclusion: These results indicate that the
enhanced expression of PADI2 mRNA in BM CD34+ cells plays a pivotal role in the
pathogenesis of RA, and might be closely associated with mRNA expression of PADI4
or Sp1.

figver1.jpg


Disclosure: T. Nagai, None; T. Tomita, None; H. Yoshikawa, None; S. Hirohata, None.

To cite this abstract in AMA style:

Nagai T, Tomita T, Yoshikawa H, Hirohata S. The Expression of mRNA for Peptidylarginine Deiminase Type 2 and Type 4 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-expression-of-mrna-for-peptidylarginine-deiminase-type-2-and-type-4-in-cd34-cells-of-the-bone-marrow-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-expression-of-mrna-for-peptidylarginine-deiminase-type-2-and-type-4-in-cd34-cells-of-the-bone-marrow-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology